Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.81 million shares were traded.
Ratios:
We take a closer look at ALDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.39 and its Current Ratio is at 6.39. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 03 ’25 when PERCEPTIVE ADVISORS LLC sold 3,400,000 shares for $1.42 per share. The transaction valued at 4,828,000 led to the insider holds 5,875,851 shares of the business.
Machatha Stephen sold 16,041 shares of ALDX for $75,975 on Aug 12 ’24. The Chief Development Officer now owns 236,771 shares after completing the transaction at $4.74 per share. On Aug 12 ’24, another insider, Greenberg Bruce, who serves as the insider of the company, sold 10,834 shares for $4.74 each. As a result, the insider received 51,313 and left with 126,382 shares of the company.
Stock Price History:
Over the past 52 weeks, ALDX has reached a high of $7.20, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is -43.69%, while the 200-Day Moving Average is calculated to be -56.33%.
Shares Statistics:
A total of 60.05M shares are outstanding, with a floating share count of 58.16M. Insiders hold about 2.90% of the company’s shares, while institutions hold 56.07% stake in the company.
Earnings Estimates
The current rating of Aldeyra Therapeutics Inc (ALDX) is the result of assessments by 5.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.16 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.69 and -$1.32 for the fiscal current year, implying an average EPS of -$0.96. EPS for the following year is $0.29, with 4.0 analysts recommending between $1.52 and -$0.53.
Revenue Estimates
Based on 5 analysts’ estimates, the company’s revenue will be $76.03M in the next fiscal year. The high estimate is $160M and the low estimate is $13M.
